7 Rue des Chasseurs Ardennais
Impiegati a tempo pieno:
|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Frank Hazevoets||MD, CEO, CFO & Director||N/D||N/D||1966|
|Dr. Vincent Bille Ph.D.||Head of Technical Operations||N/D||N/D||N/D|
|Attorney M. Grégory Nihon||Compliance Officer & Gen. Sec.||N/D||N/D||N/D|
|Mr. François Gary||Bus. Devel. & Marketing Director||N/D||N/D||N/D|
|Ms. Marie Pierre Beaumont||Head of HR||N/D||N/D||N/D|
|Ms. Béatrice De Vos Bcpm, M.D., Ph.D.||Chief Medical Officer||7,5k||N/D||N/D|
|Mr. Philippe Ghem||Head of Commercial Operations & Licensing||N/D||N/D||N/D|
|Mr. Rémy von Frenckell||Head of Clinical Devel.||N/D||N/D||N/D|
|Ms. Martine Draguet||Head of Regulatory Affairs & Quality Assurance||N/D||N/D||N/D|
DMS Imaging SA, a biopharmaceutical company, focuses on the research, development, and commercialization of immunotherapy products for the treatment of allergies in Belgium. Its lead product is gp-ASIT+, which is in the Phase III trial for the treatment of grass pollen. The company is also developing hdm-ASIT+ for the treatment of house dust mite allergy; and pnt-ASIT+ for the treatment of peanut allergy. The company was formerly known as ASIT Biotech S.A. and changed its name to DMS Imaging SA in February 2022. DMS Imaging SA was incorporated in 1997 and is based in Liege, Belgium.
L'ISS Governance QualityScore di DMS Imaging SA al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.